Ozempic represents a major advance in the treatment of type 2 diabetes. This injectable medication based on semaglutide has revolutionized the management of diabetic patients since its approval by the FDA in 2017 and by the EMA in 2018. With over 5 million prescriptions in the United States in 2024, Ozempic has established itself as an essential therapeutic reference.
This treatment belongs to the class of GLP-1 receptor agonists, a family of medications that mimic the action of a natural hormone to regulate blood glucose. Beyond its efficacy in glycemic control, Ozempic offers cardiovascular benefits and significant weight loss, making it a particularly attractive treatment for overweight patients.
What is Ozempic and how does it work?
Ozempic contains semaglutide, a molecule that mimics the action of GLP-1 (Glucagon-Like Peptide-1), a natural intestinal hormone. This hormone plays a crucial role in regulating blood glucose by stimulating insulin secretion only when blood glucose is high, thereby reducing the risk of hypoglycemia.
Ozempic’s mechanism of action is threefold:
- Stimulation of insulin secretion: Semaglutide activates GLP-1 receptors in pancreatic beta cells, promoting glucose-dependent insulin production.
- Inhibition of glucagon: It reduces the secretion of glucagon, a hormone responsible for increasing hepatic glucose production.
- Slowing of gastric emptying: This action contributes to the feeling of satiety and helps control appetite.
According to a study published in the New England Journal of Medicine in 2024, the efficacy of semaglutide in reducing HbA1c averages 1.5% after 6 months of treatment, with an average weight loss of 6.2 kg.
Clinical efficacy and cardiovascular benefits
Recent clinical studies confirm the remarkable efficacy of Ozempic. The SUSTAIN-6 study, published in the NEJM and updated in 2024, demonstrates a significant reduction in major cardiovascular events by 26% in patients treated with semaglutide.
Results on glycemic control:
- HbA1c reduction of 1.2% to 1.8% depending on dosage
- 63% of patients achieve an HbA1c target below 7%
- Long-term efficacy maintenance (2-year studies)
Proven cardiovascular benefits:
- 26% reduction in the risk of non-fatal myocardial infarction
- 39% decrease in the risk of non-fatal stroke
- 18% reduction in cardiovascular mortality
A 2024 meta-analysis including over 15,000 patients confirms these results and positions Ozempic as a treatment of choice for diabetic patients with high cardiovascular risk. The European Medicines Agency (EMA) also extended its recommendations in 2024 to include cardiovascular prevention in Ozempic’s indications.
Side effects and important considerations
Like any medication, Ozempic can cause side effects that are important to be aware of. The most frequently reported adverse effects are gastrointestinal in origin and generally occur at the beginning of treatment.
Common side effects (>10% of patients):
- Nausea (16-20% of patients according to 2024 studies)
- Diarrhea (12-15% of cases)
- Vomiting (8-12% of patients)
- Abdominal pain (7-10% of cases)
Less common but important side effects:
- Acute pancreatitis (less than 0.1% of cases)
- Gallbladder disorders (1.5% of patients)
- Diabetic retinopathy (ophthalmological monitoring recommended)
A 2024 pharmacovigilance study conducted by the FDA on over 2 million patients confirms Ozempic’s favorable safety profile, with a treatment discontinuation rate due to adverse effects of only 8.5%.
Absolute contraindications:
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia type 2 syndrome
- Hypersensitivity to semaglutide or excipients
Administration and medical follow-up
Ozempic comes as a pre-filled pen for weekly subcutaneous injection. This administration frequency promotes therapeutic adherence compared to daily treatments.
Recommended dosage regimen:
- Initial dose: 0.25 mg once weekly for 4 weeks
- Maintenance dose: 0.5 mg once weekly
- Maximum dose: 1 mg once weekly if needed
The injection can be administered at any time of day, with or without meals. Recommended injection sites are the thigh, abdomen, or upper arm, with rotation of injection points.
Essential medical follow-up:
Regular medical follow-up is essential to optimize treatment efficacy and safety. Your doctor will monitor:
- HbA1c evolution every 3 months
- Kidney function (creatinine, GFR)
- Weight and BMI
- Clinical signs of pancreatitis or biliary disorders
It is crucial never to start, modify, or stop Ozempic treatment without medical supervision. Only a healthcare professional can assess if this treatment is suitable for your particular situation.
Conclusion
Ozempic represents a major therapeutic advance in the management of type 2 diabetes. Its demonstrated clinical benefits, both in glycemic control and cardiovascular protection, make it a first-line treatment for many patients. 2024 data confirm its excellent safety profile and sustained long-term efficacy.
However, as with any medical treatment, the prescription of Ozempic requires a thorough medical evaluation and regular follow-up. If you have type 2 diabetes, do not hesitate to discuss with your doctor the benefits this innovative treatment could offer you as part of a comprehensive management plan for your diabetes.